
|Videos|April 5, 2018
Improving Clinical Trials in the Community Setting
Author(s)James Hamrick, MD
James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Advertisement
James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
3
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
4
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
5







































